The Aurora Funds is a venture capital firm that provides capital, connections and strategic guidance to entrepreneurs with early-stage healthcare and information technology companies. Founded in 1994, Aurora manages over $234 million in five venture funds. The firm’s six investment professionals have over 100 years of combined venture capital investing and operational experience. The Aurora team has managed investments in over 60 companies, resulting in five IPOs and eight M&A transactions to date.
Aurora typically is a lead or co-lead investor in seed and early-stage financing opportunities located primarily in the Southeastern and mid-Atlantic United States. The firm’s initial investment size ranges from $50,000 in a seed investment to as much as $2.5 million in a first round financing. Aurora has the capacity to invest a total of between $4 million and $8 million across multiple rounds of financing as the company matures.
The firm has a balanced investment focus across both healthcare and information technology industries.
Healthcare areas of interest include:
- medical devices
- healthcare services
- healthcare IT
Information technology areas of interest include:
- Internet infrastructure
- semiconductors and related processing technology
- emerging technologies, such as, photonics and nanotechnology
In addition, our dual investment focus enables the firm to successfully target industries that bridge these two areas, such as:
- healthcare information technology and informatics
- bio-medical engineering applications
Aurora is strategically located in the heart of the Research Triangle Park (RTP) area of North Carolina, and surrounded by leading technology corporations and world-class research universities. Aurora has been actively involved in the spinout and investment in companies with founders from many organizations, including, Duke University, University of North Carolina at Chapel Hill, North Carolina State University, Cisco, Ericsson, HAHT Commerce, IBM, Novartis, Research Triangle Institute, Closure, and GlaxoSmithKline.